Where Does Anticholinergic Therapy Fit in Moderate to Severe Asthma?

Slides:

Advertisements

Similar presentations

New Therapeutic Options for COPD

Advertisements

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Asthma Diagnosis Prescribing Acute Management Tracey Bradshaw Respiratory Consultant RIE.

1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.

Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.

Impact of Montelukast on Symptoms of Mild-to-Moderate Persistent Asthma and Exercise-Induced Asthma: The ASTHMA Survey The ASTHMA* survey was supported.

Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.

CS-1 Safety of Foradil ® Gregory P. Geba, MD, MPH Vice President – US Head RDI Clinical Development and Medical Affairs Novartis Gregory P. Geba, MD, MPH.

C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.

Component 4 Medications.

This parameter is most useful for documentation of severity of asthma (a)PEFR (b)FEV1 (c)FVC (d)FEV25.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:

ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.

An Update in Pediatric Asthma DR.NUFOUD AL- SHAMMARI CONSULTANT PEDIATRIC PULMONOLOGIST CHAIRPERSON OF MUBARK AL-KABEER HOSPITAL KUWAIT.

Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in the Treatment of Adults with Chronic Asthma Kevin Dennis Pacific University School.

Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma Stephen P. Peters, M.D., Ph.D., Susan J. Kunselman, M.A., Nikolina Icitovic, M.A.S.,

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

Attaran D, Mashhad university of medical sciences.

β2 Agonists Albuterol and other inhaled short-acting selective β2 agonists are indicated for treatment of intermittent episodes of bronchospasm and are.

Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

The Advanced Role of Tiotropium in

Global Initiative for Asthma (GINA) Teaching slide set 2017 update

Research where it is most needed National Respiratory Strategy

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Monitoring asthma in primary care

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

The Nurse View.

Practical Recommendations for COPD:

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma Willem M.C. van Aalderen, MD, PhD, Jonathan Grigg,

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Long-Term Treatment of VTE: Case Studies

Goals of Therapy for Patients With UC

COPD Management.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Medication Nonadherence in Gout

Optimizing Outcomes in the Management of GIST

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Advances in Severe Asthma Perspectives From San Antonio 2015

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Long-Term Treatment of VTE: Case Studies

Scientific Update.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Nurse Practitioners: At the Forefront of HPV-Related Disease Prevention.

The efficacy and safety of omalizumab in pediatric allergic asthma

Pathophysiologic Targets of Allergic Asthma

Binge Eating Disorder.

Chronic Obstructive Pulmonary Disease

Practical Recommendations for COPD:

Introduction Project At Crown Street Surgery:

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

The Asthma Treatment Gap

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Hyperpolarized Helium 3 MRI in Mild-to-Moderate Asthma: Prediction of Postbronchodilator Reversibility a b Helium 3 (3He) MRI ventilation defects at.

Presentation transcript:

Where Does Anticholinergic Therapy Fit in Moderate to Severe Asthma?

Introduction

Introduction (cont)

Uncontrolled Severe Asthma Is a Significant Problem

Asthma in Europe

Prevalence of Asthma in Children

Uncontrolled Asthma Checklist

Adults and Adolescents 12 Years and Older

Adults and Adolescents 12 Years and Older (cont)

AEs of OCSs

Children 6 to 11 Years Old

Adverse Outcomes from OCS: Long-Term Observational Study

AEs of OCSs

Tiotropium in Asthma Poorly Controlled With ICS/LABA

Tiotropium in Asthma Poorly Controlled With ICS/LABA (cont)

Tiotropium or Salmeterol as Add-On Therapy to ICS for Moderate Symptomatic Asthma

Tiotropium or Salmeterol as Add-On Therapy to ICS for Moderate Symptomatic Asthma (cont)

Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose ICS

Tiotropium Efficacy

Tiotropium Safety

Adults and Adolescents 12 Years and Older

Uncontrolled Asthma Checklist

How to Improve Adherence

What Are the Possible Reasons for Poor Disease Control?

Odds Ratio of an Acute Response to a Short-Acting Bronchodilator to Predict a Clinical Response to a Long-Acting Bronchodilator

Adults and Adolescents 12 Years and Older

Conclusions